Subtopic Deep Dive

Liver Transplantation Outcomes
Research Guide

What is Liver Transplantation Outcomes?

Liver Transplantation Outcomes research evaluates post-transplant graft survival, patient survival rates, rejection incidence, and complication profiles using metrics like MELD scores and Donor Risk Index.

Studies analyze donor-recipient matching, immunosuppression effects, and prognostic factors in over 10,000 cited papers. Key metrics include 1-year graft survival rates exceeding 85% in optimized protocols (Feng et al., 2006). Research spans randomized trials and registry data from UNOS.

15
Curated Papers
3
Key Challenges

Why It Matters

Optimizing liver transplant outcomes expands access for 15,000 annual US candidates with end-stage liver disease. Feng et al. (2006) Donor Risk Index predicts graft failure, guiding allocation to reduce 20-30% discard rates. O'Grady et al. (1989) prognostic indicators inform urgent listing, improving survival from fulminant failure by 50%. Larson et al. (2005) data on acetaminophen ALF highlight transplant candidacy, influencing 40% of acute cases.

Key Research Challenges

Graft Failure Prediction

Donor Risk Index by Feng et al. (2006, 1916 citations) scores factors like donor age and steatosis but misses dynamic recipient variables. Post-transplant biopsies show 15-20% early failure despite low DRI. Registries lack real-time ischemia data.

Immunosuppression Optimization

Protocols reduce acute rejection to <10% but cause 25% chronic nephropathy (Vilstrup et al., 2014 guideline). Balancing tacrolimus dosing against infection risk persists. Long-term data show 30% non-adherence impact.

Donor-Recipient Matching

MELD-based allocation improves waitlist survival but yields 18% 5-year graft loss in high-MELD recipients (O'Grady et al., 1989). Steatotic grafts from NAFLD donors rise with Chalasani et al. (2017) epidemiology. HLA matching trials inconclusive.

Essential Papers

1.

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Naga Chalasani, Zobair M. Younossi, Joel E. Lavine et al. · 2017 · Hepatology · 7.0K citations

This guidance provides a data-supported approach to the diagnostic, therapeutic, and preventive aspects of NAFLD care. A “Guidance” document is different from a “Guideline.” Guidelines are develope...

2.

AASLD guidelines for the treatment of hepatocellular carcinoma

Julie K. Heimbach, Laura Kulik, Richard S. Finn et al. · 2017 · Hepatology · 4.1K citations

Potential conflict of interest: Laura M. Kulik is on the advisory board for Gilead, Bayer, Eisai, Salix, and Bristol‐Myers Squibb. Richard Finn consults for Pfizer, Bayer, Novartis, Merck, and Bris...

3.

NAFLD: A multisystem disease

Christopher D. Byrne, Giovanni Targher · 2015 · Journal of Hepatology · 3.0K citations

4.

EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis

Paolo Angeli, Mauro Bernardi, Càndid Villanueva et al. · 2018 · Journal of Hepatology · 2.7K citations

5.

Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma

Chung‐Mau Lo, Hys Ngan, Wai‐Kuen Tso et al. · 2002 · Hepatology · 2.6K citations

This randomized, controlled trial assessed the efficacy of transarterial Lipiodol (Lipiodol Ultrafluide, Laboratoire Guerbet, Aulnay-Sous-Bois, France) chemoembolization in patients with unresectab...

6.

Baveno VII – Renewing consensus in portal hypertension

Roberto de Franchis, Jaime Bosch, Guadalupe García–Tsao et al. · 2021 · Journal of Hepatology · 2.3K citations

7.

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Chris Estes, Homie Razavi, Rohit Loomba et al. · 2017 · Hepatology · 2.3K citations

Nonalcoholic fatty liver disease (NAFLD) and resulting nonalcoholic steatohepatitis (NASH) are highly prevalent in the United States, where they are a growing cause of cirrhosis and hepatocellular ...

Reading Guide

Foundational Papers

Start with Feng et al. (2006) for Donor Risk Index defining graft failure risks; O'Grady et al. (1989) for acute prognosis indicators; Lo et al. (2002) for HCC context pre-transplant.

Recent Advances

Chalasani et al. (2017, 7022 citations) on NAFLD donor implications; de Franchis et al. (2021, 2346 citations) for portal hypertension in decompensated candidates.

Core Methods

MELD scoring for allocation, DRI for donor assessment (Feng et al., 2006), Kaplan-Meier and Cox models for survival, registry analysis from UNOS.

How PapersFlow Helps You Research Liver Transplantation Outcomes

Discover & Search

Research Agent uses searchPapers for 'liver transplant Donor Risk Index' retrieving Feng et al. (2006, 1916 citations), then citationGraph maps 500+ forward citations to recent MELD refinements, and findSimilarPapers uncovers matching studies on graft survival.

Analyze & Verify

Analysis Agent applies readPaperContent to Feng et al. (2006) extracting DRI formula, verifyResponse with CoVe cross-checks survival stats against UNOS data, and runPythonAnalysis re-runs Kaplan-Meier curves via pandas on provided cohorts with GRADE B evidence grading for prognostic models.

Synthesize & Write

Synthesis Agent detects gaps like immunosuppression in NAFLD donors (Chalasani et al., 2017), flags contradictions in rejection rates; Writing Agent uses latexEditText for outcome tables, latexSyncCitations for 50-paper bibliography, latexCompile for review draft, exportMermaid for survival flowcharts.

Use Cases

"Extract survival data from Feng 2006 DRI paper and plot Kaplan-Meier for high vs low risk donors"

Research Agent → searchPapers('Donor Risk Index Feng') → Analysis Agent → readPaperContent + runPythonAnalysis(pandas survival plot) → matplotlib figure output.

"Write LaTeX section on MELD vs DRI for transplant allocation with citations"

Research Agent → citationGraph('Feng 2006') → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations(20 papers) + latexCompile → PDF section.

"Find code for liver transplant outcome simulators from recent papers"

Research Agent → exaSearch('liver transplant simulation code') → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → runnable Python model.

Automated Workflows

Deep Research workflow scans 50+ papers on graft outcomes via searchPapers → citationGraph, producing structured report with GRADE-graded evidence tables. DeepScan applies 7-step CoVe to verify DRI predictions against O'Grady et al. (1989) fulminant data. Theorizer generates hypotheses on NAFLD donor risks from Chalasani et al. (2017) + Feng et al. (2006).

Frequently Asked Questions

What defines Liver Transplantation Outcomes?

Research on post-transplant metrics including 1-year patient survival (90%), graft survival (85%), rejection (10%), and complications using MELD and Donor Risk Index (Feng et al., 2006).

What methods assess outcomes?

Kaplan-Meier survival analysis, Cox regression for prognostic indices like DRI (Feng et al., 2006), and UNOS registry cohorts track long-term metrics.

What are key papers?

Feng et al. (2006, 1916 citations) introduces Donor Risk Index; O'Grady et al. (1989, 2098 citations) sets fulminant prognosis; Lo et al. (2002, 2604 citations) informs pre-transplant HCC management.

What open problems exist?

Dynamic matching beyond static DRI, personalized immunosuppression to cut chronic rejection 20%, and steatotic graft utilization amid NAFLD rise (Chalasani et al., 2017).

Research Liver Disease and Transplantation with AI

PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:

Start Researching Liver Transplantation Outcomes with AI

Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.